Antibody Fragments Is Expected To Grow at a CAGR of 5.9% by 2032 | Fact.MR

The antibody fragments market is currently valued at USD 7.56 billion and is expected to grow at a compound annual growth rate (CAGR) of 5.9% during the forecast period. The market is to reach USD 13.41 Billion by 2032.

The increasing number of cancer cases around the world contributes to the antibody fragments market growth, which will eventually replace the full-length antibody. These are smaller and more easily penetrated, making them useful in the treatment of diseases like cancer, tumors, and COVID-19.

Download Free Sample Copy of This Report:

https://www.factmr.com/connectus/sample?flag=S&rep_id=7995

Due to the expansion of regional pharmaceutical industries, which resulted in rising demand for antibody fragments, North America dominated the antibody fragments market with a revenue share of more than 50.0%. The increased incidence of immunodeficiency diseases and cancer has boosted the economy for antibody fragments for research purposes.

The work to develop the medical tourism market in the Asia Pacific is anticipated to drive significant growth over the forecast period. Due to the increased attention on the biologics manufacturing sector, India and China are predicted to lead the antibody fragments market.

Key Takeaways

• The specificity segment of monoclonal antibodies in the market for antibody fragments had the highest revenue share of more than 95.0%.

• The FAB type segment captured the highest revenue share of 85.0% as the first generation of antibody fragments.

• Ranibizumab in the therapy segment generated the most revenue in the market for antibody fragments.

• Due to the disease's increasing prevalence, immunodeficiency in the application segment had the highest revenue share of more than 85.0%.

• With a revenue share of more than 50.0%, North America dominated the antibody fragments market.

• The developing Asia Pacific antibody fragments market is expected to drive significant growth.

• The United Kingdom dominates the European antibody fragments market with a 26.8% share.

Share Your Requirements & Get Customized Reports :

https://www.factmr.com/connectus/sample?flag=RC&rep_id=7995

Competitive Landscape

Key antibody fragments market players are concentrating their efforts on entering new markets and developing new products. The antibody fragments market presence of key manufacturers is being strengthened by their expansion strategy, new product launches and approvals, agreements, partnerships, collaborations, and developed distribution channels such as online sales.

Key Companies Profiled:

• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Sanofi
• Biogen Inc. and Eli Lilly and Co.

Recent Development

• In March 2021, Wuxi Biologics signed an equity agreement with Pfizer to acquire its biologics drug substance and drug manufacturing facilities in China, as well as the workforce. This acquisition may help Wuxi expand its drug substance and drug product portfolio in China.

• In March 2021, AGC Biologics opened a new manufacturing facility in Italy to increase its manufacturing capacity and implement viral vector suspension capabilities. Such expansions may aid the company's position in the CDMO market.

• In August 2020, Avid Bioservices agreed to a contract with Mapp Biopharmaceutical Inc. for the clinical development of novel human monoclonal antiviral antibodies.

Key Segments

By Specificity

• Monoclonal Antibodies
• Polyclonal Antibodies

By Type

• FAB
• scFv
• sdAb
• Others

By Therapy

• Monoclonal Antibodies
• PAB
• Pipeline

By Application

• Cancer
• Immunodeficiency
• Others

By Region

• North America
• Latin America
• Asia Pacific
• MEA
• Europe

Full Access to this Report Is Available:

https://www.factmr.com/checkout/7995

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global antibody fragments market for the period of 2022-2032.

The study divulges essential insights into the market on the basis of By Specificity (Monoclonal Antibodies, Polyclonal Antibodies), By Type (FAB, scFv, sdAb, Others ), By Therapy (Monoclonal Antibodies, PAB, Pipeline), By Application (Cancer, Immunodeficiency, Others), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).

Explore Fact.MR's More Insights on the Healthcare Domain

Skincare Device Market: https://www.prnewswire.com/news-releases/sales-of-skincare-devices-to-surpass-uss-43-48-bn-as-prevalence-of-dermatological-diseases-increases-factmr-report-301506974.html

ENT Medical Devices Market: https://www.prnewswire.com/news-releases/ear-nose-throat-ent-medical-devices-manufacturers-target-applications-in-cataract--glaucoma-treatment-factmr-301262063.html

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of industry research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.